K.J. Harrison & Partners Inc Invests $3.33 Million in Eli Lilly and Company (NYSE:LLY)

K.J. Harrison & Partners Inc bought a new stake in Eli Lilly and Company (NYSE:LLY - Free Report) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 5,704 shares of the company's stock, valued at approximately $3,325,000.

Several other hedge funds have also bought and sold shares of the company. Boyd Watterson Asset Management LLC OH boosted its stake in shares of Eli Lilly and Company by 12.4% during the 4th quarter. Boyd Watterson Asset Management LLC OH now owns 13,651 shares of the company's stock worth $7,957,000 after acquiring an additional 1,510 shares during the period. Callan Capital LLC boosted its position in Eli Lilly and Company by 169.6% during the fourth quarter. Callan Capital LLC now owns 2,828 shares of the company's stock worth $1,648,000 after purchasing an additional 1,779 shares during the period. O Brien Greene & Co. Inc increased its holdings in shares of Eli Lilly and Company by 3.9% in the fourth quarter. O Brien Greene & Co. Inc now owns 943 shares of the company's stock valued at $550,000 after purchasing an additional 35 shares during the last quarter. Bryn Mawr Capital Management LLC increased its holdings in shares of Eli Lilly and Company by 52.1% in the fourth quarter. Bryn Mawr Capital Management LLC now owns 5,058 shares of the company's stock valued at $2,948,000 after purchasing an additional 1,732 shares during the last quarter. Finally, Providence First Trust Co bought a new position in shares of Eli Lilly and Company in the fourth quarter valued at about $274,000. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Eli Lilly and Company Price Performance

NYSE:LLY traded up $8.64 during trading hours on Friday, hitting $733.51. The company's stock had a trading volume of 1,998,801 shares, compared to its average volume of 3,021,320. Eli Lilly and Company has a twelve month low of $380.77 and a twelve month high of $800.78. The company has a debt-to-equity ratio of 1.69, a current ratio of 0.94 and a quick ratio of 0.73. The stock has a fifty day simple moving average of $761.79 and a 200-day simple moving average of $666.06. The company has a market capitalization of $696.95 billion, a P/E ratio of 126.47, a PEG ratio of 1.60 and a beta of 0.34.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its earnings results on Tuesday, February 6th. The company reported $2.49 EPS for the quarter, topping analysts' consensus estimates of $2.30 by $0.19. The firm had revenue of $9.35 billion during the quarter, compared to analysts' expectations of $8.95 billion. Eli Lilly and Company had a net margin of 15.36% and a return on equity of 51.22%. The business's revenue for the quarter was up 28.1% compared to the same quarter last year. During the same quarter in the prior year, the business earned $2.09 earnings per share. On average, analysts anticipate that Eli Lilly and Company will post 12.51 EPS for the current fiscal year.

Insider Transactions at Eli Lilly and Company

In related news, major shareholder Lilly Endowment Inc sold 54,032 shares of the firm's stock in a transaction on Monday, January 29th. The stock was sold at an average price of $645.07, for a total transaction of $34,854,422.24. Following the sale, the insider now owns 99,488,598 shares of the company's stock, valued at approximately $64,177,109,911.86. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Company insiders own 0.13% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on LLY shares. Wells Fargo & Company upped their price target on shares of Eli Lilly and Company from $700.00 to $825.00 and gave the company an "overweight" rating in a research note on Tuesday, February 6th. Erste Group Bank raised Eli Lilly and Company from a "hold" rating to a "buy" rating in a report on Wednesday, April 3rd. BMO Capital Markets boosted their price target on Eli Lilly and Company from $710.00 to $865.00 and gave the company an "outperform" rating in a research note on Wednesday, February 7th. Morgan Stanley increased their price objective on Eli Lilly and Company from $805.00 to $950.00 and gave the stock an "overweight" rating in a research report on Friday, February 16th. Finally, DZ Bank cut shares of Eli Lilly and Company from a "buy" rating to a "hold" rating and set a $820.00 target price for the company. in a research report on Wednesday, February 21st. Three analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company. Based on data from MarketBeat.com, Eli Lilly and Company currently has an average rating of "Moderate Buy" and a consensus target price of $728.05.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.